Contact Us
Center for Rare Disease Therapies535 Watson Drive
Claremont, CA 91711 Phone: (909) 607-0120
Email: CRDT
Advisory Board
The advisory board brings together representatives of each of the groups essential to the success of the Center for Rare Disease Therapies. Its members are individuals with broad expertise and wide influence in the biomedical industry, government agencies, patient organizations, and research institutions.
Dennis Fenton, PhD
Former Executive Vice President, Amgen, and Chair, Center Advisory Board
Daniel Bradbury, DMS
President and CEO, Amylin Pharmaceuticals
Tim Coté, MD, MPH
Director, Office of Orphan Products Development, Food and Drug Administration
Robert Curry, PhD
Partner, Alliance Technology Ventures and Chairman of the KGI Board of Trustees
Diane Dorman
Vice President for Public Policy, National Organization for Rare Disorders (NORD)
Steven Groft, PharmD
Director, Office of Rare Diseases, National Institutes of Health (NIH)
Richard Haas
Professor of Neurosciences and Pediatrics, UCSD Medical Center
Marlene Haffner, CEO, MD, MPH
Health Policy and Global Drug Development Consultant, Haffner Associates, LLC
Warren Holmes
Vice President, Organizational Resources and Health Policy, Sigma-Tau Pharmaceuticals
Peter Barton Hutt, LLB, LLM
Senior Counsel, Covington & Burling
Andy Johnson, PhD
Professor and Dean of the School of Global and Community Health, Claremont Graduate University
Richard Jove, PhD
Director, Beckman Research Institute, City of Hope
Greg Lapointe, MBA
CEO, Sigma-Tau Pharmaceuticals
Peter Saltonstall
President and Chief Executive Officer, National Organization for Rare Disorders (NORD)
Sheldon M. Schuster, PhD
President, KGI
David Wheadon, MD
Senior Vice President Scientific and Regulatory Affairs, PhRMA
Barbara Wuebbels, RN, MS
Manager, Medical Affairs Investigator Relations, Biomarin Pharmaceuticals Inc.